Acetaminophen safety and hepatotoxicity - where do we go from here?

被引:82
作者
Amar, Patrick J. [1 ]
Schiff, Eugene R. [1 ]
机构
[1] Univ Miami, Miller Sch Med, Div Hepatol, Miami, FL 33136 USA
关键词
acetaminophen; hepatotoxicity; liver disease mechanism; metabolism; NSAIDs; overdose; paracetamol; safety;
D O I
10.1517/14740338.6.4.341
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acetaminophen has been widely used for > 50 years in the treatment of pain and fever and provides for the safe and effective relief of these symptoms. In a small minority of patients, however, acetaminophen is responsible for life-threatening liver injury and accounts for up to 50% of all adult cases of acute liver failure in the US. Although approximately two-thirds of adult overdoses are associated with suicide attempts, many are inadvertent, often due to the use of multiple acetaminophen formulations over many days. Additionally, some individuals appear to experience acetaminophen toxicity at 'therapeutic' doses of < 4 g/day, for reasons unknown. In pediatric populations, the overwhelming majority of acetaminophen overdoses are due to unintentional overdoses, except for the predominance of suicidal ingestions in the teenage population. This article seeks to review the mechanism and metabolism of acetaminophen and the features of toxicity in adults, pediatric and special populations. Additionally, expert opinion is presented herein to aid in reducing the frequency and severity of liver injury from acetaminophen.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 86 条
  • [1] ABERNETHY DR, 1985, J PHARMACOL EXP THER, V234, P345
  • [2] Pediatric acetaminophen overdose -: Risk factors associated with hepatocellular injury
    Alander, SW
    Dowd, MD
    Bratton, SL
    Kearns, GL
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (04): : 346 - 350
  • [3] Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats
    Alloui, A
    Chassaing, C
    Schmidt, J
    Ardid, D
    Dubray, C
    Cloarec, A
    Eschalier, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 443 (1-3) : 71 - 77
  • [4] Metabolism of paracetamol in children with chronic liver disease
    AlObaidy, SS
    McKiernan, PJ
    Po, ALW
    Glasgow, JFT
    Collier, PS
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (1-2) : 69 - 76
  • [5] ANDREASEN PB, 1979, ACTA MED SCAND, P99
  • [6] Legislation restricting paracetamol sales and patterns of self-harm and death from paracetamol-containing preparations in Scotland
    Bateman, D. N.
    Gorman, D. R.
    Bain, M.
    Inglis, J. H. C.
    House, F. R.
    Murphy, D.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) : 573 - 581
  • [7] ACETAMINOPHEN IN CHRONIC LIVER-DISEASE
    BENSON, GD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (01) : 95 - 101
  • [8] Blot W J, 2000, J Epidemiol Biostat, V5, P137
  • [9] Orally administered paracetamol does not act locally in the rat formalin test - Evidence for a supraspinal, serotonin-dependent antinociceptive mechanism
    Bonnefont, J
    Alloui, A
    Chapuy, E
    Clottes, E
    Eschalier, A
    [J]. ANESTHESIOLOGY, 2003, 99 (04) : 976 - 981
  • [10] Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases
    Boutaud, O
    Aronoff, DM
    Richardson, JH
    Marnett, LJ
    Oates, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) : 7130 - 7135